Patient-Reported Consequences of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease

Pasquale, Cara; Vietri, Jeffrey; Choate, Radmila; McDaniel, Angee; Satō, Reiko; Ford, Kimbal D.; Malanga, Elisha; Yawn, Barbara P.

doi:10.15326/jcopdf.6.2.2018.0144

Cited by 9 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite advances in antimicrobial therapy, CAP continues to be a significant cause of morbidity and mortality in adults, resulting in more than 60,000 deaths annually. The risk of developing CAP is six to eight times higher in people with COPD compared to healthy individuals [11,112]; these patients also have an increased risk for morbidity, mortality, and economic burden [112,113]. CAP hospitalization is also more prevalent among the elderly and in patients with co-morbidities, which are a growing proportion of the population.…”

Section: Resultsmentioning

confidence: 99%

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin

et al. 2020

View full text Add to dashboard Cite

Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality both in the USA and globally. As the burden of CAP continues to increase due to several factors, the advances in its diagnosis, prevention, and treatment have taken on even greater interest and importance. The majority of CAP patients are treated empirically, and selection of appropriate antibiotic treatment is increasingly difficult because the epidemiology of CAP is changing, in part due to antimicrobial resistance, and the causative CAP pathogens differ between countries and regions. There is also an increasing prevalence of chronic co-morbid diseases among CAP patients. Treatment of CAP has become challenging because of these factors along with the varying safety profiles and efficacy of well-established antibiotics, as well as limited new therapeutic options. Recently, however, new antibiotics have been approved, which will expand the treatment options for CAP, particularly in those patients with underlying complications. Recently approved delafloxacin, an anionic fluoroquinolone, has a unique structure and distinct chemical characteristics; it demonstrated non-inferiority to moxifloxacin in a phase III clinical trial, but was shown to be superior to moxifloxacin at early clinical response in CAP patients who also have chronic obstructive pulmonary disease (COPD) or asthma as a co-morbidity, and in CAP patients who may have severe illness. Delafloxacin could offer an additional therapy against resistant isolates and among these difficult-to-treat patients. This review summarizes the development, latest research, and safety profile of the new antibiotic delafloxacin, and its potential future role in the treatment of CAP.

show abstract

Section: Resultsmentioning

confidence: 99%

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Accentuating the urgency for more knowledge are the recent pandemics caused by H1N1 influenza and SARS-CoV-2, which frequently result in concurrent viral and bacterial pneumonia [2][3][4]. There is evidence that viral and bacterial pneumonia share host vulnerabilities including winter season, older age, male sex, obesity, pre-existing cardiopulmonary conditions, and diabetes [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Increased Risk of Autopsy-Proven Pneumonia with Sex, Season and Neurodegenerative Disease

Beach¹,

Russell²,

Sue³

et al. 2021

Preprint

View full text Add to dashboard Cite

There has been a markedly renewed interest in factors associated with pneumonia, a leading cause of death worldwide, due to its frequent concurrence with pandemics of influenza and Covid-19 disease. Reported predisposing factors to both bacterial pneumonia and pandemic viral lower respiratory infections are wintertime occurrence, older age, obesity, pre-existing cardiopulmonary conditions and diabetes. Also implicated are age-related neurodegenerative diseases that cause parkinsonism and dementia. We investigated the prevalence of autopsy-proven pneumonia in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), a longitudinal clinicopathological study, between the years 2006 and 2019 and before the beginning of the Covid-19 pandemic. Of 691 subjects dying at advanced ages (mean 83.4), pneumonia was diagnosed postmortem in 343 (49.6%). There were 185 subjects without dementia or parkinsonism while clinicopathological diagnoses for the other subjects included 319 with Alzheimer’s disease dementia, 127 with idiopathic Parkinson’s disease, 72 with dementia with Lewy bodies, 49 with progressive supranuclear palsy and 78 with vascular dementia. Subjects with one or more of these neurodegenerative diseases all had higher pneumonia rates, ranging between 50 and 61%, as compared to those without dementia or parkinsonism (40%). In multivariable logistic regression models, male sex and a non-summer death both had independent contributions (ORs of 1.67 and 1.53) towards the presence of pneumonia at autopsy while the absence of parkinsonism or dementia was a significant negative predictor of pneumonia (OR 0.54). Male sex, dementia and parkinsonism may also be risk factors for Covid-19 pneumonia. The apolipoprotein E4 allele, as well as obesity, chronic obstructive pulmonary disease, diabetes, hypertension, congestive heart failure, cardiomegaly and cigarette smoking history, were not significantly associated with pneumonia, in contradistinction to what has been reported for Covid-19 disease.

show abstract

“…This finding is consistent with those of the two previously cited studies [14,15], since there was no association between pneumonia and increased mortality at 30 days, although an association was found in the long term, possibly owing to COPD itself more than to pneumonia. This observation could be explained by the possibility that, despite being an acute disease, pneumonia leads to the deterioration of symptoms and quality of life in patients with COPD [16], which may not be fully recovered after resolution of pneumonia, thus leading to poorer long-term progress.…”

Section: Discussionmentioning

confidence: 99%

“…Various studies have shown that the presence of COPD worsens the course of patients with pneumonia [14,15], although few studies have focused on patients with COPD and thus have shown the effect of pneumonia on this disease. In this sense, Pasquale et al [16] studied symptoms and quality of life in patients diagnosed with COPD who had pneumonia, although they did not analyze data on the consumption of health care resources and mortality resulting from pneumonia.…”

Section: Introductionmentioning

confidence: 99%

Influence of Pneumonia on the Survival of Patients with COPD

Vázquez

Cano

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Pneumonia is a frequent infection. Chronic obstructive pulmonary disease (COPD) can present with comorbidities, including pneumonia. It is known that COPD worsens the evolution of pneumonia, but few studies describe the impact of pneumonia on COPD evolution. This study analyzes the influence of pneumonia on the survival of COPD patients. Methods: Observational study of a cohort of 273 patients with COPD who attended spirometry in 2011, with a prospective follow-up of six years. Patients were divided into two groups according to their acquisition of pneumonia during follow-up. The difference in survival between the two groups was analyzed. Results: Survival was lower in the group with pneumonia compared with that without pneumonia (p = 0.000), both globally and after stratification by COPD phenotype. Pneumonia (Hazard Ratio -HR- 2.65; 95% Confidence Interval -CI- 1.57–4.48), advanced age (HR 1.08; 95% CI 1.03–1.09), and high Charlson index (HR 1.31; 95% CI 1.17–1.47) were identified as risk factors independently associated with mortality, while a high body mass index (HR 0.92; 95% CI 0.87–0.96) was identified as a protective factor. Conclusions: Pneumonia is associated with worse prognosis in COPD patients. It is important to take into account this comorbidity for a comprehensive care of these patients.

show abstract

Patient-Reported Consequences of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease

Abstract: For personal use only. Permission required for all other uses.

Cited by 9 publications

References 34 publications

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin

Increased Risk of Autopsy-Proven Pneumonia with Sex, Season and Neurodegenerative Disease

Influence of Pneumonia on the Survival of Patients with COPD

Contact Info

Product

Resources

About